scholarly journals Thyroid‐stimulating hormone within the normal range and risk of major adverse cardiovascular events in nonischemic dilated cardiomyopathy patients with severe left ventricular dysfunction

2018 ◽  
Vol 42 (1) ◽  
pp. 120-128 ◽  
Author(s):  
Xiaofei Li ◽  
Yan Yao ◽  
Zhaoran Chen ◽  
Siyang Fan ◽  
Wei Hua ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Left Ventricular Dysfunction ◽  
Cardiovascular Events ◽  
Ventricular Dysfunction ◽  
Thyroid Stimulating Hormone ◽  
Left Ventricular ◽  
Major Adverse Cardiovascular Events ◽  
Normal Range ◽  
Severe Left Ventricular Dysfunction ◽  
Nonischemic Dilated Cardiomyopathy

scholarly journals Left Ventricular Geometry and Replacement Fibrosis Detected by cMRI Are Associated with Major Adverse Cardiovascular Events in Nonischemic Dilated Cardiomyopathy

2020 ◽  
Vol 9 (6) ◽  
pp. 1997 ◽  
Author(s):  
Bianca Olivia Cojan-Minzat ◽  
Alexandru Zlibut ◽  
Ioana Danuta Muresan ◽  
Carmen Cionca ◽  
Dalma Horvat ◽  
...  
Keyword(s):  
Dilated Cardiomyopathy ◽  
Cardiovascular Events ◽  
Left Ventricular ◽  
Left Ventricular Geometry ◽  
Major Adverse Cardiovascular Events ◽  
Increased Risk ◽  
Replacement Fibrosis ◽  
Nonischemic Dilated Cardiomyopathy ◽  
Cox Analysis ◽  
A Prospective Study

To investigate the relationship between left ventricular (LV) long-axis strain (LAS) and LV sphericity index (LVSI) and outcomes in patients with nonischemic dilated cardiomyopathy (NIDCM) and myocardial replacement fibrosis confirmed by late gadolinium enhancement (LGE) using cardiac magnetic resonance imaging (cMRI), we conducted a prospective study on 178 patients (48 ± 14.4 years; 25.2% women) with first NIDCM diagnosis. The evaluation protocol included ECG monitoring, echocardiography and cMRI. LAS and LVSI were cMRI-determined. Major adverse cardiovascular events (MACEs) were defined as a composite outcome including heart failure (HF), ventricular arrhythmias (VAs) and sudden cardiac death (SCD). After a median follow-up of 17 months, patients with LGE+ had increased risk of MACEs. Kaplan-Meier curves showed significantly higher rate of MACEs in patients with LGE+ (p < 0.001), increased LVSI (p < 0.01) and decreased LAS (p < 0.001). In Cox analysis, LAS (HR = 1.32, 95%CI (1.54–9.14), p = 0.001), LVSI [HR = 1.17, 95%CI (1.45–7.19), p < 0.01] and LGE+ (HR = 1.77, 95%CI (2.79–12.51), p < 0.0001) were independent predictors for MACEs. In a 4-point risk scoring system based on LV ejection fraction (LVEF) < 30%, LGE+, LAS > −7.8% and LVSI > 0.48%, patients with 3 and 4 points had a significantly higher risk for MACEs. LAS and LVSI are independent predictors of MACEs and provide incremental value beyond LVEF and LGE+ in patients with NIDCM and myocardial fibrosis.

scholarly journals P626 Peripartum cardiomyopathy with persistent ventricular dysfunction and intracavitary thrombosis despite treatment with dopamine receptors agonist. The role of the three-dimensional echocardiography

2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
Z Y Vasquez-Ortiz ◽  
R Gonzalez-Varela ◽  
J Navarrete Garcia ◽  
P Hernandez-Reyes ◽  
J Oseguera Moguel
Keyword(s):  
Heart Failure ◽  
Dilated Cardiomyopathy ◽  
Left Ventricular Dysfunction ◽  
Clinical Case ◽  
Ventricular Dysfunction ◽  
Left Ventricular ◽  
Peripartum Cardiomyopathy ◽  
Left Ventricular Ejection ◽  
Severe Left Ventricular Dysfunction ◽  
Gradual Improvement

Abstract Introduction Peripartum cardiomyopathy (MPP) is a type of cardiomyopathy characterized by heart failure secondary to left ventricular systolic dysfunction during the last month of pregnancy or in the first 5 months of puerperium without other apparent etiology, being a diagnosis of exclusion. The left ventricle is not always dilated, but the fraction of left ventricular ejection is always less than 45%. The natural history and prognosis of the disease is diverse. Ventricular dysfunction is usually transient and normalizes at 3-6 months in up to 60% of cases. Mortality is variable, with reports ranging from 0 to 28%, affecting more certain ethnic groups, in patients with persistent ventricular dysfunction, evidence of the efficacy of a specific treatment beyond optimal medical therapy for heart failure is limited. Clinical case We present the clinical case of a 22-year-old woman, who was referred to the our institute with an acute heart failure syndrome two months after the end of her first pregnancy. On admission to the hospital, dilated cardiomyopathy and intracavitary thrombi were documented by transthoracic echocardiography (TTE) with dilatation and eccentric left ventricular hypertrophy, generalized hypokinesia and mobile thrombi inside, the largest of 34x16mm with severe left ventricular dysfunction 3D LVEF of 28% and global longitudinal strain (GLS) of -5.8%, pulmonary hypertension and right ventricular dysfunction with severe functional tricuspid regurgitation. Other specific etiologies of dilated cardiomyopathy were investigated and discarded, finally establishing the diagnosis of peripartum cardiomyopathy. The support management was carried with inotropic, diuretic, supplemental oxygen and parenteral anticoagulation was initiated, with gradual improvement. Subsequently, optimal medical treatment was started for heart failure, cabergoline and vitamin K antagonist. He was released to his home on II NYHA. Two months later she presented with progressive dyspnea, increased abdominal perimeter. On March 14, 2018, a TTE was performed, with absence of improvement in conventional and advanced ventricular function parameters. Apical thrombi of smaller size compared with previous study, severe left ventricular dysfunction, which worsened with respect to the previous echocardiogram, with 3D LVEF of 25% and GLS 3.7% Discussion We present the case of a woman with MPP, in whom persistent left ventricular dysfunction after 6 months of diagnosis, although cabergoline scheme in addition to optimal medical management for heart failure, with no improvement. In patients who dont present an adequate response to the management, it is necessary to consider enlisting for heart transplantation. Abstract P626 Figure. TTE, severe ventricular dysfunction

Diagnosis and outcome of dilated cardiomyopathy in the fetus

1993 ◽  
Vol 3 (1) ◽  
pp. 27-33 ◽  
Author(s):  
Steven A. Webber ◽  
George G. S. Sandor ◽  
Duncan Farquharson ◽  
Glenn P. Taylor ◽  
Sue Jamieson
Keyword(s):  
Dilated Cardiomyopathy ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Fetal Echocardiography ◽  
Left Ventricular ◽  
Outflow Obstruction ◽  
Severe Left Ventricular Dysfunction ◽  
Left Ventricular Outflow Obstruction ◽  
Ventricular Outflow Obstruction ◽  
Left Ventricular Outflow

SummaryTo identify the echocardiographic features and natural history of dilated cardiomyopathy in fetal life, we reviewed records of all fetal echocardiograms over the 10 year period 1980–1989 to identify cases of dilated cardiomyopathy without left ventricular outflow obstruction and conducted a retrospective review of the fetal echocardiograms and clinical course of those fetuses with dilated cardiomyopathy. In addition, all fetal losses, perinatal deaths and live-born infants presenting with dilated cardiomyopathy in the first seven days of life were identified from the British Columbia Pediatric Cardiovascular Pathology Registry and from inpatient records. The pathological findings and outcome for this group were also reviewed. Marked left ventricular dilatation and dysfunction without left ventricular outflow obstruction was diagnosed in five of 1,158 fetuses undergoing feta lechocardiography. These five fetuses were correctly distinguished from two others with critical aortic stenosis and severe left ventricular dysfunction. Two of the five fetuses had additional right ventricular dysfunction and dilatation and developed hydrops, while the remaining three with isolated severe left ventricular dysfunction did not and showed normal somatic growth. All fetuses were live-born with spontaneous labour occurring in four of five cases at a mean gestational age of 36.5 weeks. Four of the five infants died, with three deaths occurring in the first week of life. During the same 10 year period, two of 2450 autopsied stillbirths (both hydropic) were diagnosed with dilated cardiomyopathy. An additional 15 neonates (including the five identified by fetal echocardiography) were diagnosed in the first week of life with dilated cardiomyopathy, congenital myocarditis or endocardial fibroelastosis. Four were hydropic (all with associated right ventricular dysfunction). Only three of the 15 survive. Fetal echocardiography can accurately distinguish dilated cardiomyopathy from left ventricular outflow obstruction. In the absence of right-sided disease or premature closure of the oval fossa, severe left ventricular dysfunction is well tolerated in utero. The prognosis for fetal dilated cardiomyopathy is very poor.

Biventricular non-compaction cardiomyopathy and tricuspid hypoplasia in a novel non-POU domain-containing octamer-binding gene variant

2022 ◽  
pp. 1-5
Author(s):  
Sanam Safi ◽  
Stephen P. Sanders ◽  
Melissa Zhao ◽  
Chrystalle Katte Carreon
Keyword(s):  
Dilated Cardiomyopathy ◽  
Tricuspid Valve ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Male Infant ◽  
Left Ventricular ◽  
Pathogenic Variant ◽  
Gene Variant ◽  
Severe Left Ventricular Dysfunction ◽  
Pou Domain

Abstract A maternally inherited novel pathogenic non-POU domain-containing octamer-binding gene variant c.767G>T, p.R256I [NM_001145408], manifested in a male infant as dilated cardiomyopathy with severe left ventricular dysfunction and dilation, biventricular non-compaction, tricuspid hypoplasia, and hydrocephaly. To the best of our knowledge, no previous non-POU domain-containing octamer-binding gene variants with biventricular non-compaction have been associated with tricuspid valve hypoplasia. Hence, this case introduces a new pathogenic variant observed in the non-POU domain-containing octamer-binding gene and adds to the range of cardiac phenotypes identified in non-POU domain-containing octamer-binding gene variants.

Sign in / Sign up

Export Citation Format

Share Document